222 related articles for article (PubMed ID: 28631036)
1. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.
Du Y; Carrio I; De Vincentis G; Fanti S; Ilhan H; Mommsen C; Nitzsche E; Sundram F; Vogel W; Oyen W; Lewington V
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1671-1678. PubMed ID: 28631036
[TBL] [Abstract][Full Text] [Related]
2. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
3. Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group.
O'Sullivan JM; Carles J; Cathomas R; Gomez-Iturriaga A; Heinrich D; Kramer G; Ost P; van Oort I; Tombal B
Eur Urol Oncol; 2020 Aug; 3(4):455-463. PubMed ID: 31411991
[TBL] [Abstract][Full Text] [Related]
4. Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation.
Hosono M; Ikebuchi H; Nakamura Y; Yanagida S; Kinuya S
Ann Nucl Med; 2019 Mar; 33(3):211-221. PubMed ID: 30484260
[TBL] [Abstract][Full Text] [Related]
5. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
[TBL] [Abstract][Full Text] [Related]
6. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
[TBL] [Abstract][Full Text] [Related]
7.
Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
[TBL] [Abstract][Full Text] [Related]
8. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Heinzer H; König F; Klutmann S
Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
[TBL] [Abstract][Full Text] [Related]
9. Current approaches to incorporation of radium-223 in clinical practice.
Parker C; Heidenreich A; Nilsson S; Shore N
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):37-47. PubMed ID: 29298991
[TBL] [Abstract][Full Text] [Related]
10. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
[TBL] [Abstract][Full Text] [Related]
12. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
Rodriguez-Vida A; Torregrosa MD; Pinto Á; Climent MÁ; Olmos D; Carles J
Clin Transl Oncol; 2018 Jun; 20(6):679-686. PubMed ID: 29098556
[TBL] [Abstract][Full Text] [Related]
13. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
14. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
15. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
16. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
17. 223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient With Castration-Resistant Metastatic Prostate Cancer.
Wang J; Kuker R; Serafini A
Clin Nucl Med; 2020 Nov; 45(11):e486-e488. PubMed ID: 32657864
[TBL] [Abstract][Full Text] [Related]
18. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
Winter BM; von Rundstedt FC; Grimm MO
Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
[TBL] [Abstract][Full Text] [Related]
19. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Miranda J; Viñal D; Pinto Á
Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
[TBL] [Abstract][Full Text] [Related]
20. Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.
van der Doelen MJ; Mehra N; Hermsen R; Janssen MJR; Gerritsen WR; van Oort IM
Clin Genitourin Cancer; 2019 Apr; 17(2):79-87. PubMed ID: 30558834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
